Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Motesanib vs Bevacizumab with Chemo in Advanced Non-Squamous NSCLC
NCT00369070Phase 2Terminated
- Sponsor
- Amgen
- Start
- Jan 2007
- Primary completion
- Apr 2008
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of motesanib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Amgen. Primary endpoint: Objective Tumor Response Rate. Started Jan 2007; status: terminated.
02
Drugs
motesanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00369070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00369070.